Usefulness of isoproterenol during atrial fibrillation in evaluation of asymptomatic Wolff-Parkinson-White pattern
Identifieur interne : 004A75 ( Main/Exploration ); précédent : 004A74; suivant : 004A76Usefulness of isoproterenol during atrial fibrillation in evaluation of asymptomatic Wolff-Parkinson-White pattern
Auteurs : Tibor S. Szabo [Canada] ; George J. Klein [Canada] ; Arjun D. Sharma [Canada] ; Raymond Yee [Canada] ; Simon Milstein [Canada]Source :
- The American Journal of Cardiology [ 0002-9149 ] ; 1989.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Arrhythmia, Asymptomatic, Atrial Fibrillation (complications), Atrial Fibrillation (drug therapy), Atrial Fibrillation (physiopathology), Atrium, Cardiovascular disease, Death, Sudden (etiology), Electrodiagnosis, Electrophysiology, Evaluation Studies as Topic, Follow-Up Studies, Heart Conduction System (physiopathology), Human, Humans, Injections, Intravenous, Instrumental stimulation, Isoproterenol (administration & dosage), Isoproterenol (therapeutic use), Middle Aged, Pharmacologic test, Resuscitation, Risk Factors, Risk factor, Ventricular fibrillation, Wolff Parkinson White syndrome, Wolff-Parkinson-White Syndrome (drug therapy), Wolff-Parkinson-White Syndrome (physiopathology).
- MESH :
- chemical , administration & dosage : Isoproterenol.
- complications : Atrial Fibrillation.
- drug therapy : Atrial Fibrillation, Wolff-Parkinson-White Syndrome.
- etiology : Death, Sudden.
- physiopathology : Atrial Fibrillation, Heart Conduction System, Wolff-Parkinson-White Syndrome.
- chemical , therapeutic use : Isoproterenol.
- Adolescent, Adult, Aged, Electrophysiology, Evaluation Studies as Topic, Follow-Up Studies, Humans, Injections, Intravenous, Middle Aged, Risk Factors.
Abstract
The asymptomatic individual with a Wolff-Parkinson-White (WPW) pattern is considered at risk for ventricular fibrillation if a rapid ventricular response (shortest RR interval ≤ 250 ms) is observed during induced atrial fibrillation (AF) in the laboratory. It has been suggested that isoproterenol administration during AF may more accurately define the patient at risk. Consequently, the effect of isoproterenol on ventricular response during AF was studied in 21 asymptomatic individuals with WPW pattern to assess the potential of isoproterenol to identify patients at risk for sudden death. An electrophysiologic study that included elective induction of AF was performed. The shortest and mean RR intervals between 2 consecutive preexcited and normal QRS complexes, the average RR interval and the proportion of preexcited QRS complexes were measured in the control state and after bolus injections of isoproterenol (0.5, 1.0, 2.0 and 4.0 μg) during AF. Both atrioventricular nodal and accessory pathway conductions were enhanced proportional to isoproterenol dose. Isoproterenol had a greater effect on the atrioventricular node, as reflected by significantly greater changes in the shortest RR between normal complexes (339 ± 70 vs 255 ±21 ms, mean ± standard deviation, p < 0.001) than the shortest RR between preexcited complexes (264 ± 39 vs 219 ± 34 ms, p < 0.001) and a decrease in percentage of preexcited complexes (65 ± 37 vs 50 ± 33%, p < 0.01). After isoproterenol, 67% of patients had a shortest RR between preexcited complexes ≤ 250 ms, the traditional marker of risk for ventricular fibrillation, versus 33% in the control state. These results suggest that isoproterenol predictably accelerates the ventricular response in patients with asymptomatic WPW syndrome primarily by enhancement of atrioventricular nodal conduction. Shortening of the shortest RR interval between preexcited complexes to 250 ms occurred in 67% of patients and would be expected to have poor specificity as a potential prognosticator of ventricular fibrillation.
Url:
DOI: 10.1016/0002-9149(89)90283-X
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000122
- to stream Istex, to step Curation: 000122
- to stream Istex, to step Checkpoint: 002175
- to stream Main, to step Merge: 005426
- to stream PascalFrancis, to step Corpus: 001223
- to stream PascalFrancis, to step Curation: 000D04
- to stream PascalFrancis, to step Checkpoint: 001080
- to stream Main, to step Merge: 005477
- to stream PubMed, to step Corpus: 001C33
- to stream PubMed, to step Curation: 001C33
- to stream PubMed, to step Checkpoint: 001C33
- to stream Ncbi, to step Merge: 002293
- to stream Ncbi, to step Curation: 002293
- to stream Ncbi, to step Checkpoint: 002293
- to stream Main, to step Merge: 005338
- to stream Main, to step Curation: 004A75
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Usefulness of isoproterenol during atrial fibrillation in evaluation of asymptomatic Wolff-Parkinson-White pattern</title>
<author><name sortKey="Szabo, Tibor S" sort="Szabo, Tibor S" uniqKey="Szabo T" first="Tibor S." last="Szabo">Tibor S. Szabo</name>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
</author>
<author><name sortKey="Sharma, Arjun D" sort="Sharma, Arjun D" uniqKey="Sharma A" first="Arjun D." last="Sharma">Arjun D. Sharma</name>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
</author>
<author><name sortKey="Milstein, Simon" sort="Milstein, Simon" uniqKey="Milstein S" first="Simon" last="Milstein">Simon Milstein</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E5AC313F85EE082493CF4D674CCB88FF1011D1D1</idno>
<date when="1989" year="1989">1989</date>
<idno type="doi">10.1016/0002-9149(89)90283-X</idno>
<idno type="url">https://api-v5.istex.fr/document/E5AC313F85EE082493CF4D674CCB88FF1011D1D1/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000122</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000122</idno>
<idno type="wicri:Area/Istex/Curation">000122</idno>
<idno type="wicri:Area/Istex/Checkpoint">002175</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002175</idno>
<idno type="wicri:doubleKey">0002-9149:1989:Szabo T:usefulness:of:isoproterenol</idno>
<idno type="wicri:Area/Main/Merge">005426</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:89-0122125</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001223</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D04</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001080</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001080</idno>
<idno type="wicri:doubleKey">0002-9149:1989:Szabo T:usefulness:of:isoproterenol</idno>
<idno type="wicri:Area/Main/Merge">005477</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:2909998</idno>
<idno type="wicri:Area/PubMed/Corpus">001C33</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C33</idno>
<idno type="wicri:Area/PubMed/Curation">001C33</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001C33</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C33</idno>
<idno type="wicri:Area/Ncbi/Merge">002293</idno>
<idno type="wicri:Area/Ncbi/Curation">002293</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002293</idno>
<idno type="wicri:doubleKey">0002-9149:1989:Szabo T:usefulness:of:isoproterenol</idno>
<idno type="wicri:Area/Main/Merge">005338</idno>
<idno type="wicri:Area/Main/Curation">004A75</idno>
<idno type="wicri:Area/Main/Exploration">004A75</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Usefulness of isoproterenol during atrial fibrillation in evaluation of asymptomatic Wolff-Parkinson-White pattern</title>
<author><name sortKey="Szabo, Tibor S" sort="Szabo, Tibor S" uniqKey="Szabo T" first="Tibor S." last="Szabo">Tibor S. Szabo</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>From the Arrhythmia Service, Cardiac Investigation Unit, University Hospital, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>From the Arrhythmia Service, Cardiac Investigation Unit, University Hospital, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sharma, Arjun D" sort="Sharma, Arjun D" uniqKey="Sharma A" first="Arjun D." last="Sharma">Arjun D. Sharma</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>From the Arrhythmia Service, Cardiac Investigation Unit, University Hospital, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>From the Arrhythmia Service, Cardiac Investigation Unit, University Hospital, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Milstein, Simon" sort="Milstein, Simon" uniqKey="Milstein S" first="Simon" last="Milstein">Simon Milstein</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>From the Arrhythmia Service, Cardiac Investigation Unit, University Hospital, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">The American Journal of Cardiology</title>
<title level="j" type="abbrev">AJC</title>
<idno type="ISSN">0002-9149</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1989">1989</date>
<biblScope unit="volume">63</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="187">187</biblScope>
<biblScope unit="page" to="192">192</biblScope>
</imprint>
<idno type="ISSN">0002-9149</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0002-9149</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Arrhythmia</term>
<term>Asymptomatic</term>
<term>Atrial Fibrillation (complications)</term>
<term>Atrial Fibrillation (drug therapy)</term>
<term>Atrial Fibrillation (physiopathology)</term>
<term>Atrium</term>
<term>Cardiovascular disease</term>
<term>Death, Sudden (etiology)</term>
<term>Electrodiagnosis</term>
<term>Electrophysiology</term>
<term>Evaluation Studies as Topic</term>
<term>Follow-Up Studies</term>
<term>Heart Conduction System (physiopathology)</term>
<term>Human</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Instrumental stimulation</term>
<term>Isoproterenol (administration & dosage)</term>
<term>Isoproterenol (therapeutic use)</term>
<term>Middle Aged</term>
<term>Pharmacologic test</term>
<term>Resuscitation</term>
<term>Risk Factors</term>
<term>Risk factor</term>
<term>Ventricular fibrillation</term>
<term>Wolff Parkinson White syndrome</term>
<term>Wolff-Parkinson-White Syndrome (drug therapy)</term>
<term>Wolff-Parkinson-White Syndrome (physiopathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Isoproterenol</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Atrial Fibrillation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Death, Sudden</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Heart Conduction System</term>
<term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Isoproterenol</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Electrophysiology</term>
<term>Evaluation Studies as Topic</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Middle Aged</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Appareil circulatoire pathologie</term>
<term>Asymptomatique</term>
<term>Electrodiagnostic</term>
<term>Epreuve pharmacologique</term>
<term>Facteur risque</term>
<term>Fibrillation ventriculaire</term>
<term>Homme</term>
<term>Isoprénaline</term>
<term>Oreillette</term>
<term>Réanimation</term>
<term>Stimulation instrumentale</term>
<term>Trouble rythme cardiaque</term>
<term>Wolff Parkinson White syndrome</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The asymptomatic individual with a Wolff-Parkinson-White (WPW) pattern is considered at risk for ventricular fibrillation if a rapid ventricular response (shortest RR interval ≤ 250 ms) is observed during induced atrial fibrillation (AF) in the laboratory. It has been suggested that isoproterenol administration during AF may more accurately define the patient at risk. Consequently, the effect of isoproterenol on ventricular response during AF was studied in 21 asymptomatic individuals with WPW pattern to assess the potential of isoproterenol to identify patients at risk for sudden death. An electrophysiologic study that included elective induction of AF was performed. The shortest and mean RR intervals between 2 consecutive preexcited and normal QRS complexes, the average RR interval and the proportion of preexcited QRS complexes were measured in the control state and after bolus injections of isoproterenol (0.5, 1.0, 2.0 and 4.0 μg) during AF. Both atrioventricular nodal and accessory pathway conductions were enhanced proportional to isoproterenol dose. Isoproterenol had a greater effect on the atrioventricular node, as reflected by significantly greater changes in the shortest RR between normal complexes (339 ± 70 vs 255 ±21 ms, mean ± standard deviation, p < 0.001) than the shortest RR between preexcited complexes (264 ± 39 vs 219 ± 34 ms, p < 0.001) and a decrease in percentage of preexcited complexes (65 ± 37 vs 50 ± 33%, p < 0.01). After isoproterenol, 67% of patients had a shortest RR between preexcited complexes ≤ 250 ms, the traditional marker of risk for ventricular fibrillation, versus 33% in the control state. These results suggest that isoproterenol predictably accelerates the ventricular response in patients with asymptomatic WPW syndrome primarily by enhancement of atrioventricular nodal conduction. Shortening of the shortest RR interval between preexcited complexes to 250 ms occurred in 67% of patients and would be expected to have poor specificity as a potential prognosticator of ventricular fibrillation.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Szabo, Tibor S" sort="Szabo, Tibor S" uniqKey="Szabo T" first="Tibor S." last="Szabo">Tibor S. Szabo</name>
</noRegion>
<name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
<name sortKey="Milstein, Simon" sort="Milstein, Simon" uniqKey="Milstein S" first="Simon" last="Milstein">Simon Milstein</name>
<name sortKey="Sharma, Arjun D" sort="Sharma, Arjun D" uniqKey="Sharma A" first="Arjun D." last="Sharma">Arjun D. Sharma</name>
<name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E5AC313F85EE082493CF4D674CCB88FF1011D1D1 |texte= Usefulness of isoproterenol during atrial fibrillation in evaluation of asymptomatic Wolff-Parkinson-White pattern }}
This area was generated with Dilib version V0.6.29. |